Navigation Links
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Date:11/15/2007

Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions

BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. The Phase 1 study, which was conducted in normal volunteers, has shown good tolerance with oral bioavailability of the active ingredient, and an excellent safety profile without serious adverse reactions. The findings were released in an abstract published in the proceedings of the upcoming annual meeting of the American Society of Hematology.

G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection). Ganite(R) is marketed by Genta and approved in the U.S. for treatment of cancer-related hypercalcemia that is resistant to hydration. Low doses of the active ingredient in Ganite administered by intravenous or subcutaneous injections have shown clinical activity in a range of skeletal diseases, including hypercalcemia, bone metastasis (myeloma and breast cancer), Paget's disease, and osteoporosis.

The initial clinical trial was a Phase 1 study of escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and to assess pharmacokinetics and oral bioavailability. The drug was tested over a dosing range of the active ingredient from 30 to 150 mg, and no adverse effects attributable to G4544 were observed in this study. Initial analysis of plasma samples of low doses sh
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
(Date:1/23/2015)... Inc. (ICBU) has repositioned itself as a holding company with ... in the hydroponic, hemp and medical marijuana sectors. By acquiring ... sector, and recently partnering with the Chippewa Tribe Nation to ... iMD is committing to bring its vision to the market ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... magazine has ranked Universal SmartComp #503 overall and #35 ... 5000, an exclusive ranking of the nation,s fastest-growing private ... the most important segment of the economy—America,s independent-minded entrepreneurs. ... and Radio Flyer, maker of the iconic children,s red ...
... As the bio-pharmaceutical marketplace continues to evolve, launch leaders ... market education strategies and tactics to better reflect the ... found that a one-size-fits-all approach to education can hinder ... payers in the Oncology area have specific needs and ...
Cached Medicine Technology:Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... likely contributed to increase , , THURSDAY, March 27 ... States have increased 123 percent in a decade, with ... patients, according to new findings. , The increases occur ... which data are available. Death rates peaked in 2002, ...
... (Nasdaq: LWAY ), the country,s leading manufacturer of ... products, is opening its first,"kefir boutique" cafe with the ... several flavors of frozen kefir with over 20 toppings ... The new retail concept will debut at 1745 ...
... 37th Annual Meeting of the American Association for Dental ... in Dallas, several eminent scientists will be part of ... Friday mornings, the meeting will feature a Distinguished Lecture ... lectures will occur in the Stemmons Ballroom at the ...
... 27 Interleukin,Genetics, Inc. (Amex: ILI ) today announced ... The Company reported revenues of $9.7 million and a ... common share, for the year ended,December 31, 2007, and revenues ... $(0.05) per basic and diluted common share, for the quarter,ended ...
... safe and cost-saving solution to national problems, ... the leading,consumer brand of healthy living products, today ... filtered water bottle by the Water,Quality Association (WQA) ... new Fit & Fresh LivPURE(TM) Filtered Water Bottle ...
... results of research published a year ago , , ... says that iPods and other digital music players don,t ... published last year. , That May 2007 study concluded ... in implantable cardiac pacemakers. But cardiac electrophysiologists at Children,s ...
Cached Medicine News:Health News:Sharp Rise in U.S. Hepatitis C-Related Deaths 2Health News:Lifeway Foods Launches Starfruit, New 'Kefir Boutique' Cafe Selling Frozen Kefir & Kefir Smoothies 2Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 2Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 3Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 4Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 5Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 6Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 7Health News:Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 8Health News:Fit & Fresh(TM) Launches Filtered Water Bottle 2Health News:IPods Don't Interfere With Pacemakers, Study Shows 2
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
Angled 45 degree shafts 10 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Straight shafts with 4 mm tying platform. Serrated handle with dull finish. Most popular size or model. Overall length 3.3 inches....
Medicine Products: